NASDAQ:NK - NantKwest Stock Price, Price Target & More

$4.08 0.00 (0.00 %)

(As of 04/25/2018 04:12 AM ET)

Previous Close$4.08

Today's Range$4.04 - $4.25

52-Week Range$2.71 - $8.45

Volume143,000 shs

Average Volume229,655 shs

Market Capitalization$327.98 million

P/E Ratio-3.40

Dividend YieldN/A

Beta2.83

About NantKwest (NASDAQ:NK)

NantKwest, Inc. is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:NK

CUSIPN/A

Webwww.nantkwest.com

Phone858-633-0300

Debt

Debt-to-Equity Ratio0.01%

Current Ratio6.35%

Quick Ratio6.35%

Price-To-Earnings

Trailing P/E Ratio-3.40

Forward P/E Ratio-2.78

P/E GrowthN/A

Sales & Book Value

Annual Sales$50,000.00

Price / Sales6,448.85

Cash FlowN/A

Price / CashN/A

Book Value$2.75 per share

Price / Book1.48

Profitability

EPS (Most Recent Fiscal Year)($1.20)

Net Income$-96,420,000.00

Net Margins-214,273.34%

Return on Equity-39.04%

Return on Assets-34.03%

Miscellaneous

Employees139

Outstanding Shares79,030,000

How to Become a New Pot Stock Millionaire

NantKwest (NASDAQ:NK) Frequently Asked Questions

What is NantKwest's stock symbol?

NantKwest trades on the NASDAQ under the ticker symbol "NK."

How were NantKwest's earnings last quarter?

NantKwest (NASDAQ:NK) issued its quarterly earnings data on Monday, August, 15th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to analysts' expectations of $0.10 million. NantKwest had a negative net margin of 214,273.34% and a negative return on equity of 39.04%. View NantKwest's Earnings History.

What price target have analysts set for NK?

3 Wall Street analysts have issued 1-year target prices for NantKwest's stock. Their predictions range from $3.00 to $4.00. On average, they anticipate NantKwest's share price to reach $3.50 in the next year. View Analyst Ratings for NantKwest.

Who are some of NantKwest's key competitors?

Some companies that are related to NantKwest include REGENXBIO (RGNX), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), EntreMed (CASI), Mesoblast (MESO) and BioCryst Pharmaceuticals (BCRX).

Who are NantKwest's key executives?

NantKwest's management team includes the folowing people:

Patrick Soon-Shiong M.D., Chairman of the Board, Chief Executive Officer (Age 64)
Barry J. Simon M.D., President, Chief Operating Officer, Director (Age 52)
Steven Gorlin, Vice Chairman of the Board (Age 79)
Richard J. Tajak, Interim Chief Financial Officer (Age 64)
Sonja Nelson, Chief Accounting Officer (Age 44)
Michael D. Blaszyk, Independent Director (Age 64)
Frederick W. Driscoll, Independent Director (Age 67)
John T. Potts Jr. M.D., Independent Director (Age 85)
John C. Thomas Jr., Independent Director (Age 62)

When did NantKwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.

Has NantKwest been receiving favorable news coverage?

News coverage about NK stock has trended somewhat positive on Wednesday, according to Accern Sentiment. Accern ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NantKwest earned a news impact score of 0.15 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.73 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of NantKwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NantKwest's stock price today?

One share of NK stock can currently be purchased for approximately $4.08.

How big of a company is NantKwest?

NantKwest has a market capitalization of $327.98 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,420,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. NantKwest employs 139 workers across the globe.

How can I contact NantKwest?

NantKwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

MarketBeat Community Rating for NantKwest (NK)

Community Ranking:		2.5 out of 5 ( )
Outperform Votes:		158 (Vote Outperform)
Underperform Votes:		161 (Vote Underperform)
Total Votes:		319

MarketBeat's community ratings are surveys of what our community members think about NantKwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.

NantKwest (NASDAQ:NK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for NantKwest in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible downside of 14.22%. The high price target for NK is $4.00 and the low price target for NK is $3.00. There are currently 1 sell rating and 2 hold ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.67	1.67	2.00	2.00
Ratings Breakdown:	1 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 0 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$3.50	$3.50	$5.3333	$5.3333
Price Target Upside:	14.22% downside	29.29% downside	7.74% upside	9.30% downside

NantKwest (NASDAQ:NK) Consensus Price Target History

Price Target History for NantKwest (NASDAQ:NK)

NantKwest (NASDAQ:NK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
12/11/2017	Raymond James	Reiterated Rating	Hold		Medium
8/14/2017	Citigroup	Set Price Target	Sell	$3.00	Low
5/8/2017	Jefferies Group	Set Price Target	Hold	$4.00	Medium
3/17/2017	FBR & Co	Reiterated Rating	Outperform -> Outperform	$22.00 -> $9.00	Low
8/19/2016	Canaccord Genuity	Reiterated Rating	Buy	$18.00	N/A
8/17/2016	Piper Jaffray	Reiterated Rating	Overweight	$32.00 -> $23.00	N/A

(Data available from 4/25/2016 forward)

NantKwest (NASDAQ:NK) Earnings History and Estimates Chart

Earnings by Quarter for NantKwest (NASDAQ:NK)

NantKwest (NASDAQ:NK) Earnings Estimates

2018 EPS Consensus Estimate: ($1.57)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.35)	($0.35)	($0.35)
Q2 2018	1	($0.38)	($0.38)	($0.38)
Q3 2018	1	($0.42)	($0.42)	($0.42)
Q4 2018	1	($0.42)	($0.42)	($0.42)

NantKwest (NASDAQ NK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/7/2017	Q2 2017	($0.32)	($0.29)	$0.01 million	$0.01 million	View	N/A
5/8/2017	Q1 2017	($0.39)	($0.30)	$0.01 million	$0.01 million	View	N/A
3/15/2017	Q4 2016		($0.29)		$0.01 million	View	N/A
11/10/2016	Q3 2016		($0.39)		$0.01 million	View	N/A
8/15/2016	Q2	($0.35)	($0.41)	$0.10 million	$0.01 million	View	N/A
5/16/2016	Q1	($0.2370)	($0.38)	$0.10 million	$0.01 million	View	N/A
3/30/2016	Q4 2015		($0.97)		$0.01 million	View	N/A
11/12/2015	Q3 2015	($0.07)	($0.55)	$0.10 million	$0.01 million	View	N/A
9/10/2015	Q2 2015		($1.29)		$0.09 million	View	N/A

(Earnings results data provided by Zacks Investment Research)

NantKwest (NASDAQ:NK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

NantKwest (NASDAQ NK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 70.19%
Institutional Ownership Percentage: 15.89%

Insider Trading History for NantKwest (NASDAQ:NK)

NantKwest (NASDAQ NK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/13/2017	Steve Gorlin	Director	Sell	39,604	$5.93	$234,851.72	246,280
9/12/2017	Steve Gorlin	Director	Sell	103,841	$6.04	$627,199.64	375,002
6/20/2017	Steve Gorlin	Director	Sell	40,000	$7.78	$311,200.00	409,725
11/25/2016	John C Thomas	Director	Sell	6,168	$7.50	$46,260.00	309,621
11/23/2016	John C Thomas	Director	Sell	20,000	$7.50	$150,000.00	322,789
9/8/2016	Barry J Simon	Insider	Sell	32,000	$7.49	$239,680.00	3,334,906
12/10/2015	Angela Wilson	CFO	Buy	3,265	$15.33	$50,052.45	3,265
8/21/2015	Steve Gorlin	Director	Sell	450,000	$23.00	$10,350,000.00	455,713

(Data available from 1/1/2013 forward)

NantKwest (NASDAQ NK) News Headlines

Source:

Date	Headline
	NantKwest (NK) Downgraded to Hold at Zacks Investment Research www.americanbankingnews.com - April 18 at 8:34 PM
	NantKwest (NK) Upgraded by BidaskClub to Sell www.americanbankingnews.com - April 17 at 9:57 AM
	NantKwest (NK) Downgraded by BidaskClub www.americanbankingnews.com - April 14 at 5:18 PM
	BidaskClub Lowers NantKwest (NK) to Sell www.americanbankingnews.com - April 12 at 6:14 PM
	NantKwest (NK) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 10 at 3:25 PM
	Citigroup Analysts Give NantKwest (NK) a $3.00 Price Target www.americanbankingnews.com - April 10 at 11:28 AM
	Zacks Investment Research Lowers Nantkwest (NK) to Hold www.americanbankingnews.com - April 6 at 6:29 PM
	Nantkwest Inc (NK) Receives Consensus Rating of "Hold" from Analysts www.americanbankingnews.com - April 4 at 5:31 AM
	Nantkwest (NK) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - March 29 at 5:48 PM
	Form 4 NantKwest, Inc. For: Mar 23 Filed by: Nelson Sonja www.streetinsider.com - March 27 at 9:53 AM
	Nantkwest (NK) Upgraded by BidaskClub to Hold www.americanbankingnews.com - March 24 at 12:28 PM
	Nantkwest Inc (NK) Expected to Earn Q1 2018 Earnings of ($0.35) Per Share www.americanbankingnews.com - March 19 at 1:53 AM
	Nantkwest Inc (NK) to Post FY2022 Earnings of ($1.23) Per Share, Jefferies Group Forecasts www.americanbankingnews.com - March 16 at 4:20 PM
	NantKwest to Present at Upcoming Investment and Healthcare Conferences finance.yahoo.com - March 14 at 10:28 AM
	Nantkwest (NK) Rating Increased to Sell at BidaskClub www.americanbankingnews.com - February 24 at 11:18 AM
	Nantkwest and Frankfurt University Hospital Announce First in Human Dosing of off-the-Shelf HER2.taNK (Car–natural Killer) Cell Therapy in Glioblastoma finance.yahoo.com - February 13 at 9:08 AM
	3 Stocks Under $10 That Surged Yesterday finance.yahoo.com - February 1 at 9:15 AM
	Putin says U.S. is taking 'hostile step' finance.yahoo.com - February 1 at 9:15 AM
	Yahoo Finance Live: Market Movers - Jan 30th, 2018 finance.yahoo.com - February 1 at 9:15 AM
	Nantkwest (NK) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - January 21 at 2:16 PM
	Nantkwest Inc (NK) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - January 19 at 5:52 AM
	Nantkwest (NK) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - January 14 at 12:38 PM
	Nantkwest (NK) Upgraded to Buy at Zacks Investment Research www.americanbankingnews.com - January 6 at 10:12 AM
	ETFs with exposure to NantKwest, Inc. : December 28, 2017 finance.yahoo.com - December 28 at 3:43 PM
	NantKwest, Inc. :NK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 finance.yahoo.com - December 28 at 6:10 AM
	Head to Head Review: BioCryst Pharmaceuticals (BCRX) and Nantkwest (NK) www.americanbankingnews.com - December 26 at 6:17 PM
	Nantkwest Inc (NK) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - December 25 at 5:40 AM
	Update in Lawsuit for Investors in Nantkwest Inc. (NASDAQ: NK) Shares Announced by Shareholders Foundation finance.yahoo.com - December 12 at 10:12 AM
	Nantkwest's (NK) Hold Rating Reaffirmed at Raymond James Financial www.americanbankingnews.com - December 11 at 11:50 AM
	NantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - November 30 at 5:56 AM
	NantKwest, Inc. (NK) Raised to "Buy" at Zacks Investment Research www.americanbankingnews.com - November 25 at 8:10 PM
	NantKwest, Inc. (NK) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - November 5 at 5:52 AM
	NantKwest Becomes Oversold www.thestreet.com - November 2 at 6:51 AM
	ETFs with exposure to NantKwest, Inc. : October 11, 2017 finance.yahoo.com - October 12 at 7:28 AM
	NantKwest, Inc. (NK) Given Consensus Rating of "Hold" by Analysts www.americanbankingnews.com - October 11 at 8:49 AM
	NantKwest, Inc. (NK) Upgraded by Zacks Investment Research to Buy www.americanbankingnews.com - October 11 at 6:32 AM
	NantKwest (NK) and Its Peers Critical Comparison www.americanbankingnews.com - October 10 at 8:22 PM
	NantKwest (NK) Announces Successful First in Human Administration of CD16 haNK Cells - StreetInsider.com www.streetinsider.com - October 2 at 5:56 PM
	ETFs with exposure to NantKwest, Inc. : September 26, 2017 finance.yahoo.com - October 2 at 5:56 PM
	NantKwest (NK) Appoints Fred Driscoll to Board - StreetInsider.com - StreetInsider.com www.streetinsider.com - September 24 at 6:14 AM
	NANTKWEST (NK) SHAREHOLDER ALERT – Andrews & Springer LLC is Investigating NantKwest, Inc. for Potential Breaches of Fiduciary Duty finance.yahoo.com - September 22 at 8:52 AM
	NANTKWEST INVESTOR INVESTIGATION ALERT – Andrews & Springer LLC Is Investigating NantKwest, Inc. For Potential Breaches of Fiduciary Duty feeds.benzinga.com - September 21 at 7:13 PM
	NantKwest, Inc. (NK) Receives Consensus Recommendation of "Hold" from Brokerages www.americanbankingnews.com - September 16 at 6:36 AM
	Insider Selling: NantKwest, Inc. (NK) Director Sells 39,604 Shares of Stock www.americanbankingnews.com - September 13 at 10:22 PM
	NantKwest, Inc. (NK) Director Steve Gorlin Sells 103,841 Shares www.americanbankingnews.com - September 12 at 7:34 PM
	ETFs with exposure to NantKwest, Inc. : August 31, 2017 finance.yahoo.com - September 1 at 6:26 AM
	NantKwest, Inc. :NK-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 finance.yahoo.com - August 25 at 9:15 AM
	NantKwest, Inc. (NK) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - August 22 at 9:08 AM
	NantKwest, Inc. – Value Analysis (NASDAQ:NK) : August 15, 2017 finance.yahoo.com - August 15 at 8:32 PM
	Here's Why NantKwest Inc. Tumbled 21.1% in July finance.yahoo.com - August 10 at 6:10 AM

NantKwest (NASDAQ:NK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

NantKwest (NASDAQ:NK) Income Statement, Balance Sheet and Cash Flow Statement

NantKwest (NASDAQ NK) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff